Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161

Area of Science:

• Immunology
• Cell Biology
• Biochemistry

Background:

• CD39/ENTPD1 is an ectonucleoside triphosphate diphosphohydrolase (ENTPDase) on cell surfaces.
• CD39 is a marker for regulatory immune cells, hydrolyzing nucleotides to AMP and adenosine with CD73.
• CD39 and CD161 co-expression on human CD4(+) T cells may identify human Th17 cells.

Purpose of the Study:

• To investigate the role of CD39 and CD161 co-expression in human Th17 cells.
• To elucidate the molecular mechanisms linking CD39, CD161, and Th17 cell function.
• To explore the therapeutic potential of modulating CD39 and CD161 interactions.

Main Methods:

• Analysis of CD39 and CD161 co-expression on human CD4(+) T cells.
• Investigating molecular interactions between CD39, CD161, and acid sphingomyelinase (ASM).
• Assessing the impact of CD39/CD161 activation on ASM bio-activity, ceramide generation, and downstream signaling (STAT3, mTOR).

Main Results:

• Co-expression of CD39 and CD161 serves as a potential biomarker for human Th17 cells.
• CD39 and CD161 exhibit direct interactions linked to acid sphingomyelinase (ASM) activity.
• Activation of CD39 and CD161 enhances ASM bio-activity, leading to ceramide production and downstream signaling modulation (STAT3, mTOR).

Conclusions:

• CD39 and CD161 co-expression is a potential biomarker for human Th17 cells.
• Novel molecular mechanisms involving extracellular nucleotide and sphingolipid homeostasis control human Th17 cell responsiveness.
• These findings suggest therapeutic potential for modulating human Th17 cell activity through CD39 and CD161 pathways.